



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

**Therapeutic Goods Act 1989**  
**Approval under section 42DF for use of restricted representations by**  
**Boucher & Muir Pty Ltd**

I, Leanne McCauley, as a delegate of the Secretary to the Department of Health, on receipt of an application from Boucher & Muir Pty Ltd, have approved under section 42DF of the *Therapeutic Goods Act 1989* (the **Act**) the restricted representations described in paragraph **(A)** below for use in advertisements directed to consumers, for the product identified in paragraph **(B)**:

**(A)**

**Indication Statements:**

- (i) For the prevention and treatment of iron deficiency anaemia.
- (ii) May help relieve fatigue associate with iron and vitamin C deficiency where dietary intake is inadequate.

**Diagnosis Statement:**

For use when iron deficiency or iron deficiency anaemia has been diagnosed by the doctor and a therapeutic iron supplement is recommended.

On the basis that when the Indication Statements in (i) or (ii) above are used in advertisements, other than the label, then:

- the Diagnosis Statement must also be used; and
- the Diagnosis Statement must be displayed with equal or greater prominence than the Indication Statement.

**(B)**

- Ferropods AUST R 329091

Dated this 9th day of January 2021

*Signed electronically*

Leanne McCauley  
Delegate of the Secretary to the Department of Health  
Advertising Compliance Unit  
Regulatory Compliance Branch